Literature DB >> 23229354

Interference in coagulation testing: focus on spurious hemolysis, icterus, and lipemia.

Giuseppe Lippi1, Mario Plebani, Emmanuel J Favaloro.   

Abstract

The chance that errors might jeopardize the quality of testing is inherently present throughout the total testing process, especially in the preanalytical phase. In the coagulation laboratory, as well as in other areas of diagnostic testing, spurious hemolysis, icteria, and lipemia in test samples represent by far the leading diagnostic challenges. Interference in hemostasis testing due to spurious hemolysis is attributed to both analytical and biologic elements, namely high absorbance of cell-free hemoglobin at wavelengths used by optical instrumentation and release of both cytoplasmatic and plasma membrane molecules (e.g., tissue factor, proteases, phospholipids, and ADP) that can spuriously activate blood coagulation and platelets. The interference attributable to hyperbilirubinemia is mostly due to spectral overlap, whereas that of hypertriglyceridemia mainly reflects elements of light scatter and volume displacement as well as direct interference of lipid particles with hemostasis. In practical terms, spurious hemolysis reflects a more generalized process of endothelial and blood cell damage, so that test results on spuriously hemolyzed specimens should be systematically suppressed. The bias attributable to hyperbilirubinemia is less significant using modern coagulometers equipped with dedicated wavelengths (i.e., with readings at 650 nm or above), so that test results in samples with a bilirubin concentration up to 20 mg/dL can still be analytically reliable. The interference observed in lipemic samples is most evident with readings using wavelengths lower than 500 nm and can hence be prevented with readings at 650 nm or above, and/or using higher dilutions of the test sample, or can be abated in high hypertriglyceridemic specimens (i.e., > 1,000 mg/dL) using high speed microcentrifugation or lipid extraction with organic solvents such as fluorine-chlorinated hydrocarbon, or lipid-clearing agents such as LipoClear (StatSpin Inc., Norwood, MA) and n-hexane. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23229354     DOI: 10.1055/s-0032-1328972

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  15 in total

1.  Concordance between Activated Partial Thromboplastin Time and Antifactor Xa Assay for Monitoring Unfractionated Heparin in Hospitalized Hyperbilirubinemic Patients.

Authors:  Leana Mahmoud; Andrew R Zullo; Donald McKaig; Christine M Berard-Collins
Journal:  R I Med J (2013)       Date:  2016-03-01

Review 2.  Haemolysis index for the screening of intravascular haemolysis: a novel diagnostic opportunity?

Authors:  Giuseppe Lippi; Emmanuel J Favaloro; Massimo Franchini
Journal:  Blood Transfus       Date:  2018-05-08       Impact factor: 3.443

Review 3.  Pre-analytical issues in the haemostasis laboratory: guidance for the clinical laboratories.

Authors:  A Magnette; M Chatelain; B Chatelain; H Ten Cate; F Mullier
Journal:  Thromb J       Date:  2016-12-12

4.  Performance Evaluation of the Preanalytic Module of the ACL TOP 750 Hemostasis Lab System.

Authors:  Woo Jae Kwoun; Jeong Yeal Ahn; Pil Whan Park; Yiel Hea Seo; Kyung Hee Kim; Ja Young Seo; Ji Hun Jeong; Hwan Tae Lee
Journal:  Ann Lab Med       Date:  2018-09       Impact factor: 3.464

5.  The missing slope: paradoxical shortening of activated partial thromboplastin time in a patient on unfractionated heparin therapy.

Authors:  Ivana Lapić; Ana Lončar Vrančić; Désirée Coen Herak; Dunja Rogić
Journal:  Biochem Med (Zagreb)       Date:  2021-06-15       Impact factor: 2.313

6.  Convenience of Hgb-O detected by optical method in XN-series hematology analyzers in evaluating hemoglobin concentration in samples with chylous turbidity.

Authors:  Yu Aruga; Chiaki Ikeda; Arisa Hanai; Sakiko Yoshimura; Momoko Kito; Satoe Miyaki; Misato Tsubokura; Yuka Yasuno; Chiaki Hayashi; Motoi Miyakoshi; Takahiro Nishino; Kimihiko Kawamura; Hiromichi Matsushita
Journal:  Sci Rep       Date:  2021-07-22       Impact factor: 4.379

Review 7.  Lipemia: causes, interference mechanisms, detection and management.

Authors:  Nora Nikolac
Journal:  Biochem Med (Zagreb)       Date:  2014-02-15       Impact factor: 2.313

Review 8.  Interference of medical contrast media on laboratory testing.

Authors:  Giuseppe Lippi; Massimo Daves; Camilla Mattiuzzi
Journal:  Biochem Med (Zagreb)       Date:  2014-02-15       Impact factor: 2.313

9.  Are patients well informed about the fasting requirements for laboratory blood testing?

Authors:  Sanja Kackov; Ana-Maria Simundic; Ani Gatti-Drnic
Journal:  Biochem Med (Zagreb)       Date:  2013       Impact factor: 2.313

10.  Frequency and causes of lipemia interference of clinical chemistry laboratory tests.

Authors:  Sandhya Mainali; Scott R Davis; Matthew D Krasowski
Journal:  Pract Lab Med       Date:  2017-02-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.